{
    "nct_id": "NCT05375994",
    "official_title": "A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Adagrasib in Patients with KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 204)",
    "inclusion_criteria": "* Male or female subjects ≥ 18 years of age\n* Histologic or cytologic evidence of NSCLC\n* Known KRAS G12C mutation\n* The subject must have received prior therapy with a KRAS G12C inhibitor and experienced progression\n* Must have received appropriate treatment with at least one prior systemic regimen, but no more than 3 prior regimens, for Stage 3B-C or 4 NSCLC\n* Measurable disease according to RECIST 1.1\n* An Eastern Cooperative Group (ECOG) performance status ≤ 1\n* Adequate organ function\n* Adequate recovery from toxicities related to prior treatments\n* Agreement to use highly effective method of contraceptive\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior chemotherapy, targeted therapies, radiotherapy, immunotherapy or treatment with an investigational agent within 14 days of receipt of study drug (within 6 weeks for nitrosoureas, mitomycin C and chest radiation; within 6 months prior to Cycle 1 Day 1 for chest radiation > 30Gy)\n* History of prior malignancy, with the exception of curatively treated malignancies\n* Major surgery within 4 weeks (excluding placement of vascular access)\n* Exposure to strong CYP3A4 inhibitors or inducers within 14 days prior to the first dose and during the course of therapy\n* Exposure to strong inhibitors of breast cancer resistance protein (BCRP) within 14 days prior to the first dose and during the course of therapy\n* Symptomatic brain metastases requiring steroids or other local interventions within the 2 weeks prior to initiation of therapy\n* Known SARS-Cov2 infection ≤28 days prior to first dose of study therapy\n* Known hepatitis B, hepatitis C, or human immunodeficiency virus infection that is active\n* Active skin disorder that has required systemic therapy within the past 1 year\n* History of rhabdomyolysis or interstitial lung disease\n* Concurrent ocular disorders\n* Concurrent heart disease or severe obstructive pulmonary disease\n* Subjects with the inability to swallow oral medications",
    "miscellaneous_criteria": ""
}